Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.55    -0.05 (-8.33%)
Bid:
0.54
Ask:
0.598
Spread: 0.058 (10.741%)
Market Cap: £3.20m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Long Term Incentive Scheme

7 Dec 2007 07:00

Futura Medical PLC07 December 2007 For immediate release 7 December 2007 Futura Medical Plc ("Futura" or "the Company") Long Term Incentive Scheme Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for the consumer healthcare market, announces the introduction of along term incentive scheme for the Executive Directors under which shares willbe awarded subject to the achievement of key milestone events at the Company. The Board believes that this Long Term Incentive Scheme ("LTIS"), which has beendeveloped and reviewed over the past 12 months, is in the interests of allshareholders as it aligns the interests of the Company's Directors with those ofall other shareholders. The Executive Directors currently have beneficial interests in 1,062,687 Futurashares representing 1.8% of the Company's issued share capital and also holdexisting options over 350,000 Futura shares which currently represent 0.6% ofthe Company's issued share capital before the introduction of this LTIS. Therehave been no new grants of options to Directors since 22 March 2005. The actual quantum of the awards received by the Executive Directors will dependon achieving set milestones and the share price at the time relative to targetsset in advance. As a guide, if all the approved milestones are achieved at theshare price targets over the next 36 months then the additional shares issued inafter tax settlement would be equivalent to approximately 1.3% of the currentshare capital. The detailed scheme rules will be available shortly on theCorporate Governance pages of the Company's website. For any further information please contact:Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Canaccord Adams Tel: +44 (0) 20 7050 6500Mark Ashurst / Adria Da Breo For any media enquiries please contact:Buchanan Communications Tel: +44 (0) 020 7466 5000Mark Court / Rebecca Dietrich Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Feb 20212:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 202111:06 amRNSSecond Price Monitoring Extn
18th Feb 202111:00 amRNSPrice Monitoring Extension
15th Dec 20202:00 pmRNSPrice Monitoring Extension
15th Dec 20209:05 amRNSSecond Price Monitoring Extn
15th Dec 20209:00 amRNSPrice Monitoring Extension
8th Dec 20207:00 amRNSFutura provides US regulatory & commercial update
1st Dec 20207:00 amRNSBlock Listing Six Monthly Return
22nd Oct 20207:00 amRNSFutura provides regulatory and commercial update
21st Sep 20203:12 pmRNSDirector/PDMR Shareholding
16th Sep 20207:00 amRNSInterim Results for Six Months ended 30 June 2020
10th Sep 20204:41 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
17th Aug 20207:00 amRNSNotice of Results
10th Aug 20207:00 amRNSFutura receives positive QMS Audit Opinion
4th Aug 20207:00 amRNSFutura update on CBD100 1st Stage Development Work
24th Jul 20204:40 pmRNSSecond Price Monitoring Extn
24th Jul 20204:35 pmRNSPrice Monitoring Extension
14th Jul 20207:00 amRNSFutura Medical provides EU & US regulatory update
10th Jul 20204:31 pmRNSBlock listing Interim Review - Replacement
24th Jun 20204:22 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.